OTCMKTS:BIOVF Swedish Orphan Biovitrum AB (publ) (BIOVF) Stock Price, News & Analysis → The “Next Bitcoin”? 10 CENT Crypto Set to Explode (From True Market Insiders) (Ad) Free BIOVF Stock Alerts $22.87 0.00 (0.00%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$22.87▼$22.8750-Day Range$22.87▼$27.7952-Week Range$18.35▼$27.79VolumeN/AAverage Volume157 shsMarket CapitalizationN/AP/E Ratio31.76Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesShort Interest Get Swedish Orphan Biovitrum AB (publ) alerts: Email Address Ad True Market InsidersThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 About Swedish Orphan Biovitrum AB (publ) Stock (OTCMKTS:BIOVF)Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to treat paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.Read More BIOVF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BIOVF Stock News HeadlinesApril 26, 2024 | finance.yahoo.comSobi® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly treatment of haemophilia AApril 25, 2024 | msn.comSwedish Orphan Biovitrum AB reports Q1 resultsApril 26, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.April 25, 2024 | finance.yahoo.comSobi Q1 2024 report: Strong sales reflecting the strength of the portfolioApril 24, 2024 | markets.businessinsider.comSwedish Orphan Biovitrum AB earnings: here's what to expectApril 17, 2024 | americanbankingnews.comSwedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Short Interest UpdateApril 4, 2024 | prnewswire.comNotice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)April 2, 2024 | finance.yahoo.comSobi publishes Annual and sustainability report for 2023April 26, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.February 20, 2024 | au.finance.yahoo.comSwedish Orphan Biovitrum AB (publ) (SWOBY)February 8, 2024 | finance.yahoo.comSobi publishes Q4 2023 report: Strong revenue performance and growth into 2024February 3, 2024 | realmoney.thestreet.comSwedish Orphan Biovitrum price target raised to SEK 385 at RBC CapitalFebruary 1, 2024 | finance.yahoo.comAll You Need to Know About Swedish Orphan Biovitrum (BIOVF) Rating Upgrade to Strong BuyJanuary 24, 2024 | finance.yahoo.comInvitation: Sobi's Q4 and FY 2023 reportJanuary 5, 2024 | finance.yahoo.comSobi's Chairman of the Board resigns due to health reasonsNovember 30, 2023 | finance.yahoo.comChange in number of shares and votes in Swedish Orphan Biovitrum AB (publ)November 23, 2023 | morningstar.comSwedish Orphan Biovitrum AB BIOVFNovember 1, 2023 | finance.yahoo.comSobi has completed the issuances of series C sharesOctober 30, 2023 | msn.comSwedish Orphan Biovitrum AB Non-GAAP EPS of SEK0.54, revenue of SEK5.17BOctober 30, 2023 | finance.yahoo.comSwedish Orphan Biovitrum (BIOVF) Q3 Earnings Miss EstimatesOctober 30, 2023 | finance.yahoo.comSobi publishes Q3 2023 report: Strong revenue and solid performanceOctober 27, 2023 | finance.yahoo.comReminder: Invitation: Sobi's Q3 2023 reportOctober 18, 2023 | finance.yahoo.comInvitation: Sobi's Q3 2023 reportSeptember 15, 2023 | finance.yahoo.comReminder: Sobi KOL investor event: Advancing the standard of care in haemophiliaSeptember 8, 2023 | finance.yahoo.comSobi KOL investor event: Advancing the standard of care in haemophiliaAugust 29, 2023 | finance.yahoo.comIs Swedish Orphan Biovitrum (BIOVF) Stock Undervalued Right Now?August 22, 2023 | finance.yahoo.comSobi resolves on a rights issue of approximately SEK 6,024 millionSee More Headlines Receive BIOVF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Swedish Orphan Biovitrum AB (publ) and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/08/2024Today4/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry N/A Sub-IndustryN/A Current SymbolOTCMKTS:BIOVF CUSIPN/A CIKN/A Webwww.sobi.com Phone(468) 697-2000FaxN/AEmployees1,612Year Founded2001Profitability EPS (Most Recent Fiscal Year)$0.72 Trailing P/E Ratio31.76 Forward P/E RatioN/A P/E GrowthN/ANet Income$227.17 million Net Margins10.95% Pretax Margin13.35% Return on Equity8.93% Return on Assets3.98% Debt Debt-to-Equity Ratio0.34 Current Ratio0.66 Quick Ratio0.46 Sales & Book Value Annual Sales$2.09 billion Price / SalesN/A Cash Flow$1.90 per share Price / Cash Flow12.01 Book Value$10.82 per share Price / Book2.11Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.49 Social Links Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Guido Oelkers (Age 59)CEO & President Comp: $22.78MMr. Henrik Stenqvist (Age 57)Chief Financial Officer Mr. Torbjörn Hallberg (Age 55)General Counsel & Head of Legal Affairs Mr. Daniel Rankin (Age 44)Head of Strategy & Corporate Development Ms. Lena Bjurner (Age 56)Head of Human Resources Mr. Armin Reininger M.D. (Age 67)Ph.D., Senior Scientific & Medical Advisor Mr. Norbert Oppitz (Age 57)Head of International Mr. Sofiane Fahmy (Age 52)Head of Europe Mr. Duane H. Barnes (Age 64)Head of North America Mr. Mahmood Ladha (Age 60)Head of Strategic Transformation Operations More ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW1933 IndustriesOTCMKTS:TGIFF3SBioOTCMKTS:TRSBF4Cable TV InternationalOTCMKTS:CATV4Front VenturesOTCMKTS:FFNTFView All Competitors BIOVF Stock Analysis - Frequently Asked Questions Should I buy or sell Swedish Orphan Biovitrum AB (publ) stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Swedish Orphan Biovitrum AB (publ) in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BIOVF shares. View BIOVF analyst ratings or view top-rated stocks. How have BIOVF shares performed in 2024? Swedish Orphan Biovitrum AB (publ)'s stock was trading at $26.25 at the beginning of the year. Since then, BIOVF shares have decreased by 12.9% and is now trading at $22.87. View the best growth stocks for 2024 here. Are investors shorting Swedish Orphan Biovitrum AB (publ)? Swedish Orphan Biovitrum AB (publ) saw a increase in short interest in March. As of March 31st, there was short interest totaling 734,400 shares, an increase of 9.8% from the March 15th total of 669,100 shares. Based on an average trading volume of 200 shares, the days-to-cover ratio is currently 3,672.0 days. View Swedish Orphan Biovitrum AB (publ)'s Short Interest. How were Swedish Orphan Biovitrum AB (publ)'s earnings last quarter? Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) announced its earnings results on Thursday, February, 8th. The company reported $0.30 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.56 by $0.26. The company earned $643.39 million during the quarter, compared to analyst estimates of $668.74 million. Swedish Orphan Biovitrum AB (publ) had a trailing twelve-month return on equity of 8.93% and a net margin of 10.95%. How do I buy shares of Swedish Orphan Biovitrum AB (publ)? Shares of BIOVF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:BIOVF) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTrump is sounding the alarmPreserve GoldRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Swedish Orphan Biovitrum AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.